ADIPOA2 was one of a number of projects discussed at the A FACTT meeting in Galway this week. A FACTT is an Action to Focus and Accelerate Cell-based Tolerance-Inducing Therapies, funded through the COST (European Cooperation in Science and Technology) Programme. The meeting is being hosted by NUIG and runs from 5-7 October.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643809. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.